Manipulating active structure and function of cationic antimicrobial peptide CM15 by the polysulfonated drug suramin: a step closer to in vivo complexity by Quemé-Peña, Mayra et al.

dered—mostly a-helical—structure.[7] Because these peptides
exert their action within the membrane environment, the
membrane-associated conformational transition is believed to
be a crucial step in mediating their biological activities. This
structural transition could also be dependent on the lipid com-
position, leading to increased specificity towards membranes
enriched in negatively charged species.[1d,8]
However, the in vivo action of these peptides is a complex
issue, possibly including numerous types of interactions with
small-molecule agents. Indeed, previous studies in our group
have suggested that small molecules of both endogenous and
synthetic origin can dramatically affect the structures of AMPs,
potentially altering their mechanistic function, including their
antimicrobial efficiency.[5a,9] Similarly, it has also been observed
that several disordered AMP and protein sequences adopt
ordered secondary structures induced by the lipid mediator
lysophosphatidic acid;[10] this indicates that the presence and
use of such interactions might be widespread in organisms, a
phenomenon far from being understood.
To shed more light on this issue, this study has focused on
CM15, a short, linear, natively unfolded, synthetic hybrid AMP
combined from the silk moth cecropin A and the bee venom
peptide melittin. CM15 displays a potent broad-spectrum anti-
microbial activity, retaining the bactericidal effect of cecropins
but lacking the strong haemolytic property of melittin.[3, 5a, c, 9]
With a total charge of +6, it has a much higher average
charge per residue than its congeners. The highly cationic N-
terminal region and a mostly hydrophobic C-terminal region
separate into a hydrophilic and a hydrophobic part upon helix
formation (Scheme 1) coupled to membrane interaction. On
the basis of the above factors, CM15 was used as a model pep-
tide for preliminary screening of folding inducer effects of
anionic drugs and biomolecules.[5a] Of the biomolecules and
synthetic compounds tested on CM15, the therapeutic drug
suramin was the most potent helix promoter,[5a] and so it was
selected for this study as the most suitable candidate for ad-
dressing the more complex AMP–small molecule–lipid bilayer
interactions. Suramin is a symmetrical, hexasulfonated naph- thylurea used since 1920[11] as an anthelmintic, for treating on-
chocerciasis (African river blindness)[12] and sleeping sickness
(African trypanosomiasis).[13] Suramin also shows anticancer
and antiviral properties.[12a,14]
Using in vitro binding and functional assays, we character-
ised the interaction network of the CM15/suramin/membrane
system. The results indicate that the drug affects not only the
secondary structure of the AMP but also its membrane activity,
and that this finally results in decreased antibacterial activity.
This observation implies that as yet undetected side effects
might be identified when drugs with similar characteristics are
administered. Alternatively, it is also hoped that the insight
gained might provide a potential aspect to exploit in the de-
velopment of new strategies, in which AMP function might be
altered or even increased in a controllable manner.
Tam#s Beke-Somfai is a group leader in
the Institute of Materials and Environ-
mental Chemistry, Research Centre for
Natural Sciences, Budapest. He ob-
tained his M.Sc. (2001) in chemistry
and Ph.D. in structural chemistry
(2007) at Eçtvçs University, Budapest.
He worked as a postdoc and guest
researcher at Chalmers University of
Technology, Gothenburg, Sweden
(2008–2015). As a Marie-Skłodowska
Curie fellow he returned to Budapest
in 2015, leading the Biomolecular Self-Assembly group under the
“Momentum” excellence programme of the Hungarian Academy of
Sciences. His research involves investigation of natural and non-
natural peptide assemblies, enzyme catalysis, polarised light spec-
troscopy and membrane–biomolecule interactions.
Scheme 1. Structures of the compounds used in the study. A) Helical wheel
diagram of CM15 (KWKLFKKIGAVLKVL-amide), N and C stand for the N and
C termini of the peptide. The helix plot was drawn with HELIQUEST.[15]
B) Chemical structure of suramin. C) Chemical structures of the lipid compo-
nents used in model membranes built up of DOPC (PC) and DOPG (PG). For
mimicking mammalian and bacterial cell membranes, pure DOPC and
DOPC/DOPG (80:20, n/n%) were used throughout the study. In the chemical
structures, oxygen and nitrogen atoms are coloured red and blue, highlight-
ing negatively and positively charged parts, respectively.
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Results and Discussion
Circular dichroism study of structural changes in CM15 in
the presence of suramin and liposomes
As previously reported,[5a] the drug suramin (Sur) has proved to
be an effective folding inducer with the disordered membrane-
active peptide CM15. To aid understanding of the structural ef-
fects of suramin on the interaction between CM15 and mem-
branes, CD spectra in the presence of the interacting partners
were collected.
The far-UV CD spectrum of free CM15 measured in buffer,
with a single negative band at around 198–200 nm and no sig-
nificant shoulder in the 210–230 nm region, indicates an in-
trinsically disordered state (Figure 1A). This is in agreement
with reported observations.[5a,16] On the basis of the results pre-
sented here and in previous studies,[5a] suramin triggers the
disorder-to-order conformational transition of CM15. The char-
acteristic positive/negative couplet corresponding to p–p*
transitions at 195 and 208 nm, as well as the negative band
due to the n–p* transition at 222 nm (Figure 1A), suggest a-
helical folding of CM15.[17] Secondary structure analysis also in-
dicates increased helix content (Table S1 in the Supporting In-
formation).[5a] These spectral transformations occurred prompt-
ly after addition of the drug and are related to rapid inter-
action.
Moreover, the relatively weak CD signals might be indicative
of complex formation accompanied by aggregation; this has
been verified by dynamic light scattering (DLS) measurements
detecting particles on the micrometre scale.[5a] It is to be noted
that the intensity ratio of the CD values at 222 and 208 nm is
below &0.9 for non-interacting a-helices. In line with CD data,
this value is >1 for the CM15/suramin mixture (Figure 1A),
thus suggesting oligomerisation of the peptide chains. In
view of the net charges of +6 and @6 of CM15 and suramin,
respectively, neutral 1:1 complexes could easily assemble into
higher oligomers or aggregates as suggested previously.[5a]
Structural order gained upon interaction with membranes
was probed with dioleoyl–phosphatidylcholine (DOPC, or PC)
and dioleoyl-phosphatidylglycerol (DOPG, or PG) liposomes,
mimicking electrostatic features of mammalian and bacterial
biomembranes, respectively. Addition of neutral PC liposomes
to CM15 caused the main negative band of the peptide to be
red-shifted (from 198 to 203 nm), together with an intensity
decrease, and the unresolved negative shoulder at 222 nm to
become more pronounced (Figure 1A). This partial helical fold-
ing could be the result of a weak, rather hydrophobic interac-
tion lacking electrostatic attraction between the zwitterionic
lipids and the peptide.[5b] The outer leaflet of the mammalian
cell membrane is exclusively composed of neutral, zwitterionic
phospholipids, towards which charged peptides such as CM15
show lower affinity;[18] that is also why ionic AMPs are less
toxic towards mammalian cells.[4c, 8b, c] In contrast, upon addition
of negatively charged PC/PG liposomes, the ID peptide folds
into a definite helical conformation (Figure 1A). Helix forma-
tion is also supported by the estimated &40% helix content
for the lipid-loaded CM15 (Figure 1B and Table S1). In this
case, the driving force behind the folding could be the combi-
nation of electrostatic interactions between the positively
charged residues of the peptide and the negatively charged
PG head groups, as well as hydrophobic interactions between
the nonpolar side chains and the hydrophobic core of the lipid
bilayer.[5b,18]
To test the effect of suramin on lipid-bound peptide, titra-
tion with the drug was carried out in the presence of model
membranes. In sharp contrast to the case of the free peptide,
where addition of the drug resulted in elevated helix content,
which saturated at 1:1 molar ratio, for the lipid-bound CM15,
the suramin dependence was remarkably different (Figure 1B).
With increasing suramin concentration, the helix content first
reduced below the value of the lipid-free state in both types
of vesicles, and this was then followed by a signal increase re-
sulting in an approximately doubled helix fraction at 1:2 molar
ratio, relative to the suramin-free state (Figure 1B). However,
Figure 1. Structural changes of CM15 in the presence and in the absence of model membranes and suramin, studied by CD spectroscopy. A) Far-UV CD spec-
tra were taken at peptide, suramin and lipid concentrations of 40, 40, and 635 mm, respectively. B) Effect of suramin on the helix content of free and mem-
brane-bound CM15. The peptide (40 mm) was titrated with suramin in the absence and in the presence of liposomes (635 mm total lipid) with use of CD
buffer or PBS (for the compositions see the Experimental Section). Helix content was estimated with the aid of the BestSel online tool.[30] Data are means:
SEMs, two series of titrations were carried out with CD buffer, and a single titration in PBS was performed as a control.
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differences between the two liposome types were also re-
vealed. For the neutral PC system, the helical content rose at
high suramin ratios (>60 mm, Figure 1B). The phenomenon
could be explained in terms of nonspecific association of sura-
min above a threshold concentration on the lipid bilayer ren-
dering the neutral surface negatively charged, and this might
facilitate peptide binding and induce helical folding.
It should also be noted that titration curves following the
same trend were obtained both in the presence and in the ab-
sence of sulfate ions, resembling drug sulfonate groups (Fig-
ure 1B). Thus, it is evident that the sulfate moiety alone is not
enough to trigger the peptide conformational changes in-
duced by suramin, in which relative spatial arrangement of the
negatively charged groups as well as the separating rings act
in concert.
Altogether, these findings suggest that suramin interacts
with CM15 even in the presence of lipid bilayers and governs
peptide conformation in a concentration-dependent manner.
For examination both of peptide structural changes and of
charge neutralisation effects, mixtures with peptide/suramin
ratios of 1:1 and 1:2 were investigated throughout this study.
To determine the relative affinities of the peptide towards
lipid and small-molecule binding partners, three-component
mixtures differing only in the order of mixing of the compo-
nents were tested. In general, spectral features of the lipo-
some-containing samples more closely resemble those of the
suramin-loaded peptide than those of the lipid-bound state,
and indicate random coil-to-helix transition (Figure 2 and
Table S1). However, clear differences potentially attributable to
the binding preference of the peptide could be observed. For
systems with a CM15/suramin ratio of 1:2 (Figure 2B and D),
comparable spectra were obtained for the two-component
CM15·suramin complexes and the three-component mixtures
in which the peptide competes for the partners, (Sur+ lipid)+
CM15, thus suggesting the prevalence of peptide–drug bind-
ing over the lipid interaction. However, the strongest signal,
exceeding intensities for the pure CM15·suramin complex, was
detected with PC/PG liposomes when suramin was added to
the lipid-bound peptide (Figure 2D); this argues for the high-
est apparent ordered peptide fraction with possibly the lowest
level of aggregation for the (CM15+PC/PG)+Sur mixture. This
also points to the ability of suramin to enhance helical confor-
mation even when the peptide is already attached to the lipid
bilayer. Alternatively, variations in the spectral intensity might
be coupled to aggregation induced by the small-molecule
compound. Consistent with these observations, although the
helical character of the peptide is clear, the intensity of the CD
signal is rather low for most of the three-component mixtures
but especially with the 1:1 CM15/suramin ratio (Figure 2A and
C); this could be indicative of higher levels of aggregation.
Figure 2. Far-UV CD spectra of CM15 in the presence and in the absence of model membranes and suramin. Spectra were collected at 40 mm peptide A),
B) with PC, and C), D) with PC/PG liposomes (635 mm total lipid) at CM15/suramin ratios of A), C) 1:1, or B), D) 1:2. The order of addition in the three-compo-
nent system was varied so that the preincubation of the two compounds in parentheses was initially performed, with the third compound then being added.
ChemBioChem 2019, 20, 1578 – 1590 www.chembiochem.org T 2019 The Authors. Published by Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim1581
Full Papers
From the CD spectral features observed for the two- and
three-component systems, additional information about pep-
tide binding characteristics could be derived. The p–p* band
minimum of the PC/PG-bound CM15 is below 210 nm, whereas
for the suramin-associated peptide it is at around 210 nm (Fig-
ure 2C and D). This wavelength shift could reflect polarity
changes in peptide backbone surroundings. Specifically, the
hydrophobic environment provided by PC/PG liposomes could
increase the excitation energy of the p–p* transitions, resulting
in a blue shift. Conversely, the more polar aqueous phase
around the CM15·suramin complexes could cause a red shift of
the p–p* peak. In light of this consideration, spectral features
witnessed for three-component mixtures showing non-reduced
signals—Figure 2B and D, (Sur+ lipid)+CM15 and (CM15+PC/
PG)+Sur—are consistent with a binding scenario in which
peptide chains are not inserted into the nonpolar interior of
the lipid bilayer but rather are exposed to the bulk aqueous
phase. Furthermore, in view of suramin association to the vesi-
cles as suggested above, peptide–suramin interaction might
occur at the liposome surface.
CM15·suramin complex aggregation revealed by DLS and
electron microscopy
To monitor formation of molecular aggregates, DLS measure-
ments were conducted. As previously indicated,[5a] large associ-
ates appeared in the case of the two-component CM15/sura-
min system. They showed hydrodynamic diameters in the low-
micrometre range, also confirmed here for both 1:1 and 1:2
peptide/suramin ratios (Figure 3, Tables S2 and S3). The phe-
nomenon was explained in terms of mutual charge neutralisa-
tion in complexes made up of the cationic CM15 and its anion-
ic partner, resulting in less hydrophilic adducts that were
prone to aggregation in the aqueous environment.[5a]
Peptide binding to the lipids induced no detectable changes
in the correlation function, so a liposome size of 100 nm was
determined for the vesicle/peptide mixtures. Similarly, addition
of suramin to the model membranes caused no perturbation
of the curves. However, for the three-component systems, a
shift of the correlation function to higher decay times is consis-
tent with formation of aggregates with diameters greater than
100 nm. The estimated aggregate size, in the high-nanometre
to low-micrometre range, is similar to that measured for
CM15·suramin complexes. Large-sized associates were clearly
detected in the presence of PC liposomes, but this was not so
pronounced with PC/PG liposomes. In general, mixtures of pre-
incubated peptide and drug with subsequent addition of lipid
vesicles showed the greatest propensity to form large aggre-
gates. As an exception to this, all three-component systems
displayed large-sized particles in the presence of neutral PC lip-
osomes, thus highlighting the importance of peptide–drug
charge neutralisation in effective assembly. The association
process is also regulated by the CM15/suramin ratio, with the
size distributions of the aggregates being found to be narrow-
Figure 3. Peptide–drug assembly in the two- and three-component systems monitored by DLS. Correlation functions are shown for mixtures with CM15/sura-
min ratios of A), C) 1:1, and B), D) 1:2, in the absence and in the presence of A), B) PC, and C), D) PC/PG liposomes. Peptide, suramin and lipid concentrations
are 20, 20 or 40, and 635 mm, respectively. For more details see Tables S2 and S3.
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er in the case of the 1:2 ratio than in that of the 1:1 ratio (Ta-
bles S2 and S3). In line with this, no such dependence on the
molar ratio was observed in the case of the anionic PC/PG vesi-
cles.
Aggregate formation was further investigated by transmis-
sion electron microscopy (TEM), providing additional informa-
tion on the morphology of the CM15·suramin complex. Consis-
tent with the DLS results, TEM images for both 1:1 and 1:2
peptide/drug ratios (Figure 4) showed formations of up to 1–
2 mm in diameter with a characteristic morphology. These dis-
played networks of sphere-like building blocks of &50 nm
interconnected by rather linear regions. A similar associated
state, depicted as a beadlike branched morphology, was re-
ported for the anticancer/antimicrobial peptide LL-37 in a com-
plex with self-RNA as detected by phase-contrast-light, scan-
ning-electron and confocal fluorescence microscopy.[19] These
findings suggest that cationic amphiphilic peptides such as
CM15 and LL-37 might easily form complex aggregates with
anionic partners bearing aromatic rings with limited structural
flexibility, such as drugs or nucleotides. It should be noted that
particles with this morphology are typical for the CM15·sura-
min complex but were observed neither in peptide-only nor in
drug-only solutions.
Tryptophan fluorescence indicates altered environments in
different lipid complexes
To obtain additional information on the CM15–suramin interac-
tion in the presence of various lipid bilayers, fluorescence spec-
troscopy measurements were performed. Here we exploited
the intrinsic tryptophan fluorescence of the peptide, which
sensitively reports binding events that lead to polarity changes
in the local fluorophore environment.
The spectrum of the free peptide is characterised by an
emission maximum at 357 nm (Figure 5), consistent with a
water-accessible tryptophan of a disordered peptide. Upon ad-
dition of the liposomes, the membrane-bound state was easily
detectable through the blue shift of the maximum. This phe-
nomenon is typical for a tryptophan residue inserted in a more
nonpolar environment shielded from the aqueous phase. The
effect was more pronounced, accompanied by a significant in-
tensity increase, in the case of the negatively charged PC/PG
liposome. In contrast, the rather wide maximum in the case of
the PC-bound peptide suggests the coexistence of two trypto-
phan populations with different environments. These results
agree well with stronger peptide binding associated with more
intimate interaction with PG-containing bilayers than in the
case of the neutral PC liposome, and are also in line with the
CD-based considerations above.
Titration of CM15 with suramin resulted in a reduced emis-
sion intensity, indicating a nearby quencher group in the com-
plex (Figure 6A). If the structure of suramin (Scheme 1) is con-
sidered, the aromatic naphthyl moieties could account for the
effect, although ligand-binding-induced helical folding could
also lead to tryptophan quenching due to enhanced rigidity
and closer proximity of adjacent side chains.[20] Nevertheless,
the moderate dose-dependent intensity decrease, leading to
almost complete fluorescence loss at 50 mm drug concentra-
tion (Figure 6A), is characteristic for the CM15–suramin interac-
tion. Similarly, nearly complete loss of fluorescence upon addi-
tion of suramin was reported for the recombinant prion PrP
protein and attributed to suramin-induced aggregation,[21] a
phenomenon also detected here for CM15, as discussed
above.
For purposes of comparison, the same experiment was car-
ried out with the non-binding tryptophan control N-acetyl-
tryptophanamide (NATA), which does not form stable com-
plexes with suramin and can consequently reflect dynamic
quenching and/or inner filter effects. In this case (Figure 6B) in-
tensity loss was much weaker, and the lack of static binding of
NATA to liposomes or suramin is evident from the slight linear
suramin-dependent intensity decrease, which occurred to the
same extent both in the presence and in the absence of lipid
vesicles. Thus, the difference in quenching efficiency observed
on comparing the effects of suramin on NATA and CM15 could
be accounted for by the peptide binding of the drug.
When suramin titration was performed on lipid-loaded pep-
tide, more effective quenching was observed than in the case
of the lipid-free state, thus suggesting a different peptide–
drug binding mode (Figure 6B). For the PC system, the fluores-
Figure 4. Morphology of the CM15·suramin complex imaged by TEM. Micro-
graphs of the mixtures stained with phosphotungstic acid were taken at
CM15/suramin ratios of 1:1 (left) and 1:2 (right). Peptide and suramin con-
centrations in the solutions prior to drying were 20 and 20 or 40 mm, re-
spectively.
Figure 5. Fluorescence emission spectra of CM15 in the absence and in the
presence of model membranes. Peptide and lipid concentrations were 1 and
100 mm, respectively.
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cence loss was &85% at 1:1 and complete at a peptide/
suramin ratio of 1:2.5. PC/PG liposomes showed intermediate
behaviour closer to that of the free peptide than that of the
PC-bound state. A possible explanation for the phenomenon
could be binding of suramin to the lipid bilayer separately
from the peptide and/or to the vesicle-bound peptide, result-
ing in a better relative positioning of the putative suramin
quencher group for accessing the peptide fluorophore. If the
suramin naphthyl groups were assumed as the quenchers,
detection of more efficient quenching in the case of the PC-
bound peptide would require tryptophan situated closer to
suramin and/or in a more suitable relative orientation of the
two rings on the two components enabling better contact
than in the case of the pure peptide·drug complex. This could
relieve some “lifting out” of the lipid-loaded peptide inserted
to some depth into the bilayer, which could be easier in the
case of the PC-bound peptide, with a looser contact to the
vesicle. In contrast, the tryptophan in the peptide bound more
tightly to the PC/PG liposome could remain more firmly incor-
porated, although still located closer to the suramin quencher
part. In the latter case, drug binding would probably be less
favoured because of electrostatic repulsion between the nega-
tively charged suramin sulfonyl and PG head groups. Neverthe-
less, this binding mode assumes preferred interaction between
the N-terminal part of CM15 and the middle part of suramin
(Scheme 1) in the CM15·suramin complex, and this was indeed
predicted by means of a computational approach in our
group.[22] Moreover, similar binding characteristics involving
the membrane-associated drug could be deduced from CD
findings (see above) and from IR spectroscopy experiments
(see below).
Although the ability of suramin to quench a fluorophore
such as a tryptophan has been demonstrated here and is re-
ported in ref. [21] , suramin also has intrinsic fluorescence prop-
erties related to its naphthylamide moiety. When excited sepa-
rately from tryptophan at 315 nm, suramin emission with a
maximum near 400 nm showed remarkable enhancements of
up to tenfold in the presence of protein binding partners.[23]
However, when excited at 295 nm—the wavelength used here
for exciting tryptophan—the weak emission peak developing
at &400 nm showed no sensitivity to drug interactions with
CM15 or vesicles (data not shown).
In summary, fluorescence data suggest perturbed CM15–sur-
amin interaction with different relative conformations of the
peptide towards the binding partners in the presence of lipid
bilayers. Titration results obtained for lipid-bound CM15 are
not compatible with simple peptide displacement from the
vesicles by suramin.
Peptide partition between liposome-bound and suramin-
complexed states suggested by IR spectroscopy
The interaction between CM15 and lipid assemblies such as
vesicles has been studied by means of IR spectroscopy by sev-
eral groups.[2d,24] Bastos et al.[24d] investigated the interaction
between CM15 and liposomes formed from saturated lipids
that were also shorter than those (PC/PG) used here. By moni-
toring lipid carbonyl stretch as a function of increasing peptide
concentration, it was reported that the bilayer retained signifi-
cant order in the presence of the peptide.
Parts of IR spectra involving lipid carbonyl (ca. 1735 cm@1)
bands, as well as peptide amide I (ca. 1660 cm@1) and amide II
(ca. 1545 cm@1) bands of CM15–liposome associates (Fig-
ure 7A) were analysed. No drastic changes relating to the lipid
order in the bilayer were observed. The small shift of lipid car-
bonyl bands (from 1736 to 1735 cm@1) in the presence of the
peptide suggests that the polar/nonpolar interface in the lipid
bilayer could be involved in the interaction in the cases both
of PC and of PC/PG vesicles.
More pronounced changes were witnessed in the amide I
band of the peptide upon lipid binding. Beside the main band
at 1660 cm@1 assigned to the disordered/helical fraction, a new
Figure 6. Peptide fluorescence study of suramin binding to CM15 in the absence and in the presence of liposomes. A) Fluorescence emission spectra of CM15
(1 mm) upon addition of suramin. Arrow indicates increasing drug concentrations. B) Normalised maximum emission intensities of CM15 (1 mm) and the con-
trol NATA (1 mm) as a function of suramin concentration. Note that error bars for the peptide titration points are mostly smaller than symbol size (data are
means:SEMs, n=2).
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band component appeared at around 1684 cm@1 in the pres-
ence of liposomes. In an early study on interactions between
melittin or melittin fragments and PC vesicles, Brauner et al.[25]
observed very similar spectral features. They speculated that
the band at 1685 cm@1 arose from peptides assembled at the
lipid surface in an extended conformation.[25]
In general, there is some controversy relating to results avail-
able for CM15 and other membrane-active peptides when pep-
tide orientation relative to the bilayer is considered. It has
been argued that perpendicular insertion connected mainly to
pore formation by the surface-associated peptide might occur
above a threshold peptide concentration and peptide/lipid ra-
tio.[3, 5c,24d]
The structural changes associated with CM15–suramin inter-
action can also be monitored by IR spectroscopy (Figures 7
and 8). An important advantage of the method is that the
signal is not complicated by spectral perturbations due to the
presence of aggregates. Changes in the amide I and amide II
bands (Figure 7A) suggest a protein-like complex structure
with predominant helical conformation (corroborated by the
amide I peak centred at 1655 cm@1) connected to suramin-in-
duced oligomerisation/aggregation. Similar observations have
also been made by other methods.[5a] In addition, a remarkable
feature of the CM15·suramin complex is a sharp peak at
1040 cm@1 that is markedly separated from the buffer phos-
phate vibrations (Figure 7B). This band can be assigned to the
in-phase S@O stretching of the sulfonyl groups in the com-
plexed suramin, as also observed for suramin oligomers.[26]
Thus, the extra band at 1040 cm@1 could be used as an IR
marker for identification and approximate quantification of
CM15·suramin complex formation. We have to point out that
at the suramin concentrations used—80 and 160 mm—no such
local crowding was detected in the absence of CM15. This is in
agreement with NMR data that support the prevalence of
monomers at 0.5 mm concentration but oligomerisation at
5 mm.[27]
On the basis of the spectral changes experienced for the
two-component systems, in the three-component mixtures we
focused on the evolution of the amide I band component at
1684 cm@1, as well as on the band at 1040 cm@1, as measures
of the peptide–lipid and peptide–drug interactions, respective-
ly.
Firstly, liposome systems with 1:2 peptide/suramin ratios
were analysed (Figure 8). These revealed substantial differences
when the mixing order of the components was varied. Upon
addition of suramin to PC-bound CM15, the intensity of the
shoulder amide I band at 1684 cm@1 decreases (Figure 8A), in-
dicating competition of lipid and drug for the peptide. Howev-
er, when suramin is added first to CM15 or PC, suppression of
the amide I band component is nearly complete (Figure 8A),
thus suggesting higher affinity of CM15 towards the drug. A
similar trend was observed for the extra band at 1040 cm@1
(Figure 8B and Table S4).
From the band intensities, the largest amount of CM15·sura-
min complex was formed when the peptide and the small-mol-
ecule compound were mixed first. In the case of administration
of suramin to the PC-bound peptide, the affinity of CM15 to-
wards the liposomes is, however, only partially abolished, in
parallel with reduced CM15·suramin complex formation.
When addition of suramin to liposomes was followed by in-
corporation of the peptide, CM15·suramin complex formation
was still remarkable and no redistribution towards liposomes
was witnessed. A possible explanation for this could be lipid
binding of CM15 being strong enough to interfere with sura-
min interaction, so the liposome-loaded peptide cannot partic-
ipate in complex formation with the drug. However, this bind-
ing scenario is not in full agreement with CD and DLS results
indicating a significant fraction of CM15/suramin associates in
the presence of neutral vesicles, which points to a binding
event in which suramin can interact with liposomes and/or
lipid-bound peptide as suggested by the CD and fluorescence
results. Indeed, liposome-associated suramin causes perturba-
tion of the lipid head group region, as indicated by a shift of
the lipid asymmetric phosphate vibration (nPOas) at 1240–
1250 cm@1.
With reduced suramin concentrations at the CM15/suramin
ratio of 1:1 in the PC system (Figure S2), weaker peptide–lipo-
some interaction was observed in all of the three-component
Figure 7. IR study of CM15 binding to model membranes and suramin. A) Amide I and II regions, as well as lipid carbonyl bands, recorded for CM15/liposome
systems. B) Formation of CM15·suramin complex indicated by the appearance of an extra band at 1040 cm@1.
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mixtures, as indicated by a decline in intensity of the marker
band at 1684 cm@1 and the shift of the lipid ester carbonyl
band from 1736 to 1737 cm@1 (Figure S2A). The latter suggests
a slight lifting of CM15 from the polar/nonpolar boundary of
the bilayer upon suramin addition. On the other hand, the for-
mation of the CM15·suramin complex is less significant (Fig-
ure S2B) than in the 1:2 CM15/suramin case (Figure 8B). Never-
theless, the largest amount of peptide·drug complex was indi-
cated when vesicles were added to the CM15/suramin mixture
(Table S4).
With use of the PC/PG liposome system to mimic the nega-
tive charge of a bacterial membrane, both similarities to and
differences from the neutral PC system were found. At a 1:2
peptide/suramin ratio (Figure 8), addition of suramin diminish-
es the amide I band shoulder at 1684 cm@1 significantly but
not completely (Figure 8C). Furthermore, the marker band of
CM15–suramin association at 1040 cm@1 (Figure 8D) is less pro-
nounced (Figure 8B). This is in line with the considerations
above: namely the binding of CM15 to negatively charged lip-
osomes being stronger than that to neutral lipids, so peptide·
drug complex formation is more hindered in the former case
(see also Table S4). From these results, it can be concluded
that in the three-component systems there is competition for
CM15 between binding to the liposome surface or complex
formation with suramin. However, the (CM15+PC/PG)+Sur
mixture behaves exceptionally. For this system, both peptide
interactions seem to be diminished, according to reduced
band intensities at 1685 and 1040 cm@1. Moreover, a slight
shift of the lipid carbonyl band from 1735 to 1737 cm@1 is ob-
served; this occurs only for this mixture combination.
In contrast to PC/PG liposome systems with a 1:2 peptide/
suramin ratio, no shift of the lipid carbonyl group was ob-
served for any mixture with a 1:1 ratio (Figure S2C). Alterations
in the 1684 cm@1 marker band suggest that in cases in which
suramin is added to the PC-bound peptide, binding of CM15
to the liposome is still strong (Figure S2C). Simultaneously, for-
mation of CM15·suramin complex is also hindered, as con-
firmed by the significant intensity loss of the “complex marker”
band at 1040 cm@1 (Figure S2D and Table S4).
To summarise the findings obtained from IR measurements,
our results point to dominant peptide–drug interaction when
the lipid is added to the preformed CM15·suramin complexes.
This preference is stronger at a CM15/suramin ratio of 1:2 and
more relevant for the neutral PC system than for the charged
PC/PG system. Vesicle attachment of CM15 could be strong
enough to inhibit CM15·suramin complex formation; however,
Figure 8. IR study of CM15 interactions in the presence of model membranes and suramin. A), C) Amide I and II regions and lipid carbonyl band. B), D) Forma-
tion of CM15·suramin complex indicated by the appearance of an extra band at 1040 cm@1. ATR FTIR spectra were collected for dry films produced from solu-
tions containing CM15 (80 mm), suramin (160 mm) and PC or PC/PG liposome (1.3 mm lipid).
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interaction with suramin could result in peptide being lifted
from the bilayer interior.
Binding determinants in the three-component systems
By combining the results obtained from the biophysical meas-
urements, we can conclude a general binding scenario in
three-component CM15/suramin/lipid systems in which CM15
forms a complex with suramin at the expense of binding to
liposomes. However, not all spectral changes observed could
be explained simply in terms of peptide displacement. Pertur-
bations in the lipid head group region detected by IR spectros-
copy and suggested by fluorescence quenching point to possi-
ble binding of suramin to the vesicles or even to lipid-bound
peptide, allowing the formation of dynamic complex associ-
ates. In these assemblies, the peptide could be extruded from
the polar/nonpolar boundary of the lipid bilayer but might
preserve looser contact with the less buried regime of the lipid
head group region facing the aqueous phase.
Moreover, our findings point to the importance of mixing
order in peptide binding preference: that is, the binding part-
ner that comes into contact with CM15 first. Peptide interac-
tion with the small-molecule compound could dominate over
liposome binding when the lipid is added to preformed
CM15·suramin complexes. However, the binding preference is
also controlled by peptide/suramin ratio as well as by vesicle
composition, mainly driven by electrostatics. CM15 and sura-
min bear +6 and @6 net charges, respectively, so complex for-
mation could be initiated by electrostatic attraction between
peptide and drug. Consistently with charge neutralisation at
an equimolar ratio and the negative overall charge of the com-
plex at higher suramin concentrations, higher degrees of pep-
tide partition towards complex formation with suramin leading
to more significant aggregation were detected at 1:1 CM15/
suramin ratio and in the case of the neutral liposome system.
In contrast, vesicle attachment of CM15 could inhibit interac-
tion with the drug when suramin meets the peptide associated
tightly to the negatively charged membrane.
Our results suggested that electrostatic forces play a pivotal
role in the initiation of peptide binding and assembly. This is
consistent with previous studies in which it was assumed that
electrostatics are a key factor in AMP–membrane interac-
tions.[24d] However, in view of the amphiphilic nature of all part-
ners (CM15, suramin, lipids), hydrophobic interactions could
also contribute to the binding energetics. Indeed, CD spectra,
tryptophan fluorescence and lipid carbonyl vibration indicated
peptide regions residing close to the nonpolar interior of the
lipid bilayer. In contrast, CD and IR spectroscopic results sug-
gested a more polar environment for suramin-bound CM15
even in the presence of vesicles.
Variations in peptide structure monitored by CD and IR spec-
troscopy are compatible with a reduced content of the mem-
brane-active peptide conformation in the presence of suramin,
with this appearing to be valid even when the ability of sura-
min to interact with biomembranes is taken into account. To
test the biological relevance of the above interactions and
their potential in altering bioactivity, in vitro antibacterial and
cytotoxicity assays were performed.
Altered antibacterial activity and cytotoxicity of CM15 in the
presence of suramin
To understand the biological relevance of the AMP·drug com-
plex formation, antibacterial effects and cytotoxicity on human
cells were probed with CM15 premixed with suramin.
On the tested Escherichia coli strain, CM15 showed a remark-
able antibacterial effect, as indicated by the fact that no bacte-
rial growth was detected at peptide concentrations as low as
5 mm. In the presence of suramin, however, the peptide’s effi-
ciency was significantly decreased, with bacterial growth being
observed even at higher CM15 concentrations of 10–40 mm
(Figure 9A). To provide a more detailed picture on the effects
of suramin, bacteria were treated with 5 mm peptide preincu-
bated with excess suramin. A strong impact of the drug on the
antibacterial efficacy of CM15 is evident, with significantly
greater amounts of the bacterial cells surviving when CM15
was added with suramin (Figure 9B). Furthermore, increasing
suramin concentrations resulted in higher relative bacterial
growth. Specifically, this value at a peptide/suramin ratio of 1:2
was approximately half that at 1:8 (Figure 9B).
The membrane-disrupting activity of CM15 was also tested
with human cells, specifically with MonoMac6 monocytes and
red blood cells (RBCs). Cells were treated with CM15 in the ab-
sence or in the presence of suramin at 1:1 and 1:2 peptide/sur-
amin ratios. With the monocyte cell line, CM15 alone was
found to be cytotoxic at a relatively low concentration (IC50=
7.6 mm, Figure 10A), whereas when it was administered togeth-
er with suramin the effect was substantially decreased. Peptide
Figure 9. Antibacterial effect of CM15 in the presence and in the absence of suramin. A) E. coli treated with peptide/drug mixtures at various ratios. After 24 h
incubation, no bacterial growth was detected in the CM15-treated wells. In contrast, when CM15 was added with suramin, visible bacterial growth was ob-
served. B) Relative bacterial counts after treatment with 5 mm CM15 and various concentrations of suramin. Values are means:SEMs (n=4).
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cytotoxicity was impaired to a greater extent in the presence
of an excess of suramin (IC50 values of 19.8 and 66.9 mm for 1:1
and 1:2 ratios, respectively, Figure 10A). On treatment of red
blood cells, CM15 alone showed moderate cytotoxicity, with a
HC50 value (peptide concentration at which 50% haemolysis
occurred) of &45 mm (Figure 10B); this is consistent with the
reduced haemolytic activity of the hybrid peptide relative to
its parent melittin.[28] In the presence of suramin, no haemoly-
sis was observed (HC50>200 mm, Figure 10B). It is to be noted
that suramin alone at concentrations up to 100–200 mm
showed no effect on these cells (Figure 10A and B), which indi-
cates that reduced peptide cytotoxicity is directly connected
to CM15·suramin complex formation.
In an early work, an effective concentration of 10 mm and
typical drug dosage of 0.3 mm were reported for suramin.[11] In
a recent study, patients were treated with suramin at plasma
concentrations in the 140–190 mm range and the drug was
cleared with a 40 d period half time.[29] Because suramin can
reach high levels in vivo, the interactions investigated here are
likely to occur in the human body.
Conclusion
We have investigated the structural and functional effects of
the therapeutic drug suramin on the membrane-active antimi-
crobial peptide CM15 by a combination of several biophysical
methods. On the basis of the structural data supported by in
vitro binding assays, our findings are compatible with a model
delineating formation of dynamic complex associates of the
peptide populated in lipid-bound and/or drug-loaded forms.
CM15 partition is governed mainly by charge neutralisation
effects controlled by suramin-to-peptide ratio and lipid bilayer
composition. We have also demonstrated that interaction with
suramin changed peptide function appreciably, as illustrated
by significantly reduced antimicrobial activity on Gram-nega-
tive bacteria and diminished cytotoxicity towards mammalian
cells. In view of the low effective concentrations for both
CM15 and suramin, high drug plasma levels during medical
treatments and locally accumulated AMPs, suramin and AMP
levels can fall in the range used in this study. On the bases of
these findings and of several other small-molecule–AMP inter-
actions demonstrated recently in our group, it is proposed that
natural AMPs and host defence peptides will regularly experi-
ence alteration of their structures and functions in the complex
in vivo environment—an aspect to be considered and poten-
tially exploited during future treatments and drug design.
Experimental Section
Peptide solution : CM15 was synthesised in the solid phase by
using an automated peptide synthesiser and a standard Fmoc/tBu
strategy. Peptide product was characterised by analytical RP-HPLC,
mass spectrometry and amino acid analysis (see the Supporting In-
formation for more details). Lyophilised CM15 powder (trifluoroace-
tate salt) was dissolved in high-purity water at the indicated con-
centration (not higher than 1 mm), aliquoted and stored frozen at
@18 8C until use (no longer than a few weeks).
Suramin solution : Suramin powder (sodium salt, Calbiochem) was
dissolved in high-purity water at the indicated concentration (not
higher than 1 mm), aliquoted and stored frozen at @18 8C until
use.
Lipid solutions: High-purity synthetic 1,2-dioleoyl-sn-glycero-3-
phosphocholine (DOPC) and 1,2-dioleoyl-sn-glycero-3-[phospho-
rac-(1-glycerol)] (DOPG) were purchased from Avanti Polar Lipids,
Inc. Liposomes were prepared by the lipid thin-film hydration tech-
nique. Lipids were dissolved in chloroform (LabScan, Hungary) con-
taining methanol (Reanal, Hungary, 50 vol%) and then evaporated
with the aid of a rotary evaporator. The resulting lipid film was
kept under vacuum for at least 8 h to remove residual traces of sol-
vent. The dried lipid film was hydrated with the assay buffer. After
repeated heating (37 8C) and cooling (@196 8C) steps (at least 10
times), the solutions were extruded through polycarbonate filters
of 100 nm pore size (at least 11 times) with use of a LIPEX extruder
(Northem Lipids, Inc. , Canada). Final lipid concentration was
13 mm. For mimicking mammalian and bacterial cell membranes,
pure DOPC and DOPC/DOPG (80:20, n/n%) were used throughout
the study.
Assay conditions : To mimic physiological conditions, the assay
buffer used throughout the study was isotonic phosphate-buffered
saline [PBS, phosphate (10 mm), NaCl (137 mm), KCl (3 mm),
pH 7.4] , purchased from Sigma–Aldrich. For measuring CD spectra,
a buffer free of chloride ions [CD buffer, Na phosphate (10 mm),
Na2SO4 (100 mm), pH 7.0] was frequently used, allowing collection
of spectra down to 190 nm.
In investigation of three-component systems, the order of addition
of the components was varied. This involved preincubation of two
compounds (Comp1 and 2) for 3–4 min, followed by the incorpora-
tion of the third one (Comp3). The corresponding labelling used
throughout the text is (Comp1+Comp2)+Comp3.
Figure 10. Cytotoxic and haemolytic effects of CM15 in the presence and in
the absence of suramin. Cytotoxicity was measured with MonoMac6 human
monocytes, and haemolysis was assayed with a suspension of human RBCs
(4%, v/v). Data are means:SEMs (n=3). Note that error bars are often
smaller than the symbol size, as well as the use of a logarithmic scale for the
concentration. A) Significantly lower cytotoxicity was measured for CM15 ad-
ministered together with suramin: IC50 values for CM15 alone and for CM15/
suramin at 1:1 and 1:2 ratio are (7.6:0.2), (19.6:4.3), and (66.9:4.5) mm,
respectively, with p=0.0011 for CM15 versus CM15/Sur (1:1) and p<0.0001
for CM15 versus CM15/Sur (1:2). The effect was stronger when CM15 was
mixed with suramin at higher (1:2) molar ratio. Suramin alone showed no
cytotoxic effect (IC50>100 mm). B) Haemolytic activity of CM15 [HC50=
(45.9:1.6) mm] was abolished in the presence of suramin at both ratios
applied (HC50>200 mm). Suramin alone showed no haemolytic effect (HC50>
200 mm). Note that data points overlap for Sur, CM15/Sur (1:1) and CM15/
Sur (1:2).
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Circular dichroism (CD) spectroscopy : CD spectra were collected
with a JASCO J-1500 spectropolarimeter at room temperature in
0.1 cm path-length cylindrical quartz cuvettes (Hellma, USA). Pep-
tide CD data were collected in continuous scanning mode be-
tween 190 and 260 nm at a rate of 50 nmmin@1, with a data pitch
of 0.5 nm, response time of 4 s, 1 nm bandwidth, and three accu-
mulations. CD curves for peptide, peptide/drug, peptide/liposome
and peptide/liposome/drug samples were corrected with a blank
buffer solution. Titration with suramin in the presence and in the
absence of liposomes was performed in duplicate with use of CD
buffer and as a single experiment in PBS. To estimate CM15 secon-
dary structure content under various conditions, the software pro-
vided by the BeStSel (Beta Structure Selection) website (http://
bestsel.elte.hu)[30] was used. Data points are given as means: stan-
dard errors of means (SEMs).
Dynamic light scattering (DLS): Mean hydrodynamic diameter (Dh)
and polydispersity were measured at 20 8C with a W130i dynamic
light scattering device (DLS, Avid Nano, Ltd. , High Wycombe, UK)
with a diode laser (660 nm) and a photodiode detector. Low-
volume disposable cuvettes with 1 cm path length (UVette, Eppen-
dorf Austria, GmbH) were used. Samples containing peptide
(20 mm) and various amounts of drug and liposomes were mea-
sured in a final volume of 80 mL in PBS. The time-dependent auto-
correlation functions were measured for 10 s, this was repeated
ten times, and the average distributions were reported. The analy-
sis of the measurement data was performed with the iSize 3.0 soft-
ware, supplied with the device.
Attenuated total reflection (ATR) FTIR : FTIR spectroscopic meas-
urements were conducted with a Varian 2000 FTIR Scimitar spec-
trometer (Varian, Inc, US) fitted with a liquid-nitrogen-cooled mer-
cury/cadmium/telluride (MCT) detector and a “Golden Gate” single-
reflection diamond ATR accessory (Specac, Ltd, UK). The sample
(5 mL) was mounted onto the diamond ATR surface, and the spec-
tra were collected (2 cm@1 resolution and 64 scans) from dry films
(after slow evaporation of the buffer solvent under ambient condi-
tions). Prior to spectral evaluation, ATR correction was performed
and the corrected spectra were smoothed with use of the Savitz-
ky–Golay algorithm (polynomial degree=2, number of points=17)
and the GRAMS/32 (Galactic, Inc. , USA) software package.
Fluorescence spectroscopy : Spectra were recorded with a Jobin
Yvon Fluoromax-3 spectrofluorimeter (3 and 5 nm excitation and
emission slits, respectively), at 25 8C in PBS. To test peptide interac-
tion, the tryptophan fluorophore of CM15 was excited at 295 nm
and emission was monitored from 310 to 400 nm. Binding assays
were carried out with CM15 at 1 mm in the presence and absence
of liposomes being titrated with increasing amounts of suramin up
to 50 mm. To correct for spectral contribution of the liposomes and
suramin, appropriate blank spectra (recorded for solutions contain-
ing no fluorophore but lipid and drug at the same concentration)
were subtracted. Peptide titrations were performed in duplicate;
data presented are means:SEMs.
Transmission electron microscopy (TEM): For direct visualisation
of the structure and morphology of the sample, TEM images were
obtained with a Morgagni 268D instrument (FEI, The Netherlands).
A droplet (2 mL) of the sample prepared in PBS was pipetted onto
a 200 mesh copper grid with a support film made of formvar.
Excess liquid was removed after a 20 s contact time. Phospho-
tungstic acid (5%) was added immediately as contrast material;
then, after a contact time of 10 min, excess liquid was again re-
moved and the sample was left to air-dry.
Antibacterial test, cytotoxicity and haemolytic assay : The anti-
bacterial effect of CM15 in the presence or in the absence of sura-
min was measured with E. coli strain DSM 1103. Bacterial lyophili-
sate was resuspended in Bouillon broth and cultured in a blood
agar plate for 24 h. To test peptide efficacy, 0.5 McFarland standard
was diluted 50 times, and bacterial suspension (100 mL) was then
plated on a 96-well U-bottomed plate. Lysogeny broth (LB) was
used as culture medium. CM15 solutions alone or together with
suramin were added to the wells in a final concentration of 40, 20,
10, and 5 mm for each compound. Plates were read after 24 h incu-
bation. All samples were measured in quadruplet; data are
means:SEMs.
Cytotoxic effects of CM15 were measured with the MonoMac6
human monocytic cell line (DSMZ, ACC 124), widely used and ac-
cepted as model cells for assays of cytotoxicity, membrane
damage and cellular uptake of compounds such as peptides or
drugs.[31] Prior to the treatment, cells were cultured in serum-free
RPMI medium and plated (15000 cells, 100 mL/well) in a flat-bot-
tomed 96-well plate. CM15 was dissolved in serum-free medium at
a final concentration of 200 mm. Suramin was added to the peptide
solution at 1:1 or 1:2 molar ratio. Cells were treated with serial dilu-
tion of CM15 or CM15/suramin mixtures over the concentration
range of 0.8–100 mm in triplicate. Cells were incubated with the
compounds for 1.5 h, and cell viability was then tested by use of
the (4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) assay.[32] Briefly, MTT solution (45 mL) was added to each well
(2 mgmL@1, dissolved in serum-free medium). After 3.5 h incuba-
tion, plates were centrifuged at 430 g for 5 min, and the superna-
tant was carefully aspirated with a G30 needle. The precipitated
purple crystals were dissolved in DMSO (100 mL), and after 10 min
agitation the absorbance was determined at 540 and 620 nm with
use of an ELISA plate reader (iEMS Reader, Labsystems). Cytotoxici-
ty, expressed as a percentage as a function of peptide concentra-
tion, was plotted, and IC50 values were determined. Data are
means:SEMs (n=3).
For haemolytic activity assay, peripheral blood from a healthy vol-
unteer (purchased from the Hungarian National Blood Transfusion
Service, Budapest, Hungary) was collected in vacuum tubes con-
taining sodium citrate as anticoagulant (Vacuette, 9NC). Tubes
were centrifuged (430g, 5 min) and the pellet was washed twice
with PBS. PBS was added to the pellet to yield a final RBC suspen-
sion (4%, v/v). Stock solutions of the compounds were diluted in
PBS and twofold serial dilution series were prepared (final concen-
trations 1.6–200 mm). RBC suspension (100 mL/well) was placed in a
96-well U-bottomed cell culture plate and mixed with peptide so-
lution (100 mL). The plates were incubated for 1.5 h at 37 8C. After
centrifugation (430g, 5 min), the supernatant (50 mL) was trans-
ferred to a flat-bottomed microtiter plate and absorbance was
measured at 414/450 nm with an ELISA plate reader. Percentage
haemolysis was plotted against peptide concentration, and HC50
values were determined. Data are means:SEMs (n=3).
To analyse statistical significance (p), the Student t-test was per-
formed by using GraphPad Prism.
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